Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial-Reference-Cited by-同舟云学术

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial

Published:2015-09-07 Issue:1 Volume:69 Page:35-41
ISSN:0021-9746
Container-title:Journal of Clinical Pathology
language:en
Short-container-title:J Clin Pathol

Author:

Richman Susan D,Adams Richard,Quirke Phil,Butler Rachel,Hemmings Gemma,Chambers Phil,Roberts Helen,James Michelle D,Wozniak Sue,Bathia Riya,Pugh Cheryl,Maughan Timothy,Jasani Bharat

Publisher

BMJ

Subject

General Medicine,Pathology and Forensic Medicine

Reference14 articles.

1. Evaluating many treatments and biomarkers in oncology: a new design;Kaplan;J Clin Oncol,2013

2. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer;Douillard;N Engl J Med,2013

3. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer;Amado;J Clin Oncol,2008

4. K-ras mutations and benefit from cetuximab in advanced colorectal cancer;Karapetis;N Engl J Med,2008

5. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer;Lievre;Cancer Res,2006

Cited by 23 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Verification of molecular subtyping of bladder cancer in the GUSTO clinical trial;The Journal of Pathology: Clinical Research;2024-02

2. Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT;Efficacy and Mechanism Evaluation;2022-12

3. Energy balance‐related factors in childhood and adolescence and risk of colorectal cancer based on KRAS , PIK3CA , and BRAF mutations and MMR status;Molecular Carcinogenesis;2022-09-30

4. Energy balance-related factors and risk of colorectal cancer based on KRAS, PIK3CA, and BRAF mutations and MMR status;Journal of Cancer Research and Clinical Oncology;2022-05-11

5. FOCUS4 biomarker laboratories: from the benefits to the practical and logistical issues faced during 6 years of centralised testing;Journal of Clinical Pathology;2022-03-07